AbbVie Stock Price and Value Analysis

Should you buy AbbVie stock? (NYSE:ABBV). Let's see how it does in our automated value investing analysis system.

ABBV Free Cash Flow Trend

Free Cash Flow trendline for ABBV
Free Cash Flow trendline for AbbVie

Hmm, we can't give any reliable projection for AbbVie's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has a large dividend yield!
  • This company is not making money.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has wild ups and downs.

Inside the ABBV Numbers

ABBV Price
(AbbVie stock price per share)
[?] PE Ratio versus Sector 18% higher than other Healthcare stocks
[?] PE Ratio versus Industry 40% higher than other Drug Manufacturers - Major stocks
[?] Free Cash Flow Jitter 65%
[?] Dividend Yield 6%

Is AbbVie Stock on Sale?

Based on our analysis, we believe that you should not buy AbbVie right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ABBV Stock?

Does AbbVie have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.